TY - JOUR
T1 - Activation of signal transducer and activator of transcription (STAT) pathways in failing human hearts
AU - Ng, D.C.H.
AU - Court, N.W.
AU - Dos Remedios, C.G.
AU - Bogoyevitch, M.A.
PY - 2003
Y1 - 2003
N2 - Objectives: The signal transduction pathways mediating the progression to failure have been intensively studied in a variety of in vitro and in vivo animal models. Recently, acute activation of the Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) has been observed in the heart, but whether this is sustained in ischemic heart disease (IHD) or dilated cardiomyopathy (I)CM) has not been previously addressed. Methods: We assessed the tyrosine phosphorylation of STAT1, 3, 5 and 6 in ventricular samples of explanted human hearts with IHD (n=11) and DCM (n=9) as an indication of STAT activation. Samples from normal donor hearts (n=9) acted as controls. In parallel, we also assessed protein expression and phosphorylation of three major families of mitogen-activated protein kinases (MAPKs); ERK, p38 MAPK and c-Jun NH2-terminal kinase (JNK). Results: All STAT isoforms were significantly phosphorylated in DCM. In contrast, only the phosphorylation of STATs I and 5 were significantly enhanced in IHD. Expression of total STAT protein remained unchanged. For the MAPKs, significant phosphorylation of p38 MAPK was only observed in IHD. In contrast, there was no change in ERK or JNK activation despite abundant protein expression. Conclusions: We have shown that different members of the STAT transcription factor family are chronically phosphorylated in the failing heart as a result of IHD (STAT1 and 5) or DCM (STAT1, 3, 5 and 6). In contrast, IHD but not DCM showed significant p38 MAPK phosphorylation. Whilst the differences noted between IHD and DCM may reflect different initiating events, the common activation of STATs I and 5 suggests that these transcription factors may play a common role regulating the progression of heart failure. (C) 2003 European Society of Cardiology. Published by Elsevier Science B.V. All rights reserved.
AB - Objectives: The signal transduction pathways mediating the progression to failure have been intensively studied in a variety of in vitro and in vivo animal models. Recently, acute activation of the Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) has been observed in the heart, but whether this is sustained in ischemic heart disease (IHD) or dilated cardiomyopathy (I)CM) has not been previously addressed. Methods: We assessed the tyrosine phosphorylation of STAT1, 3, 5 and 6 in ventricular samples of explanted human hearts with IHD (n=11) and DCM (n=9) as an indication of STAT activation. Samples from normal donor hearts (n=9) acted as controls. In parallel, we also assessed protein expression and phosphorylation of three major families of mitogen-activated protein kinases (MAPKs); ERK, p38 MAPK and c-Jun NH2-terminal kinase (JNK). Results: All STAT isoforms were significantly phosphorylated in DCM. In contrast, only the phosphorylation of STATs I and 5 were significantly enhanced in IHD. Expression of total STAT protein remained unchanged. For the MAPKs, significant phosphorylation of p38 MAPK was only observed in IHD. In contrast, there was no change in ERK or JNK activation despite abundant protein expression. Conclusions: We have shown that different members of the STAT transcription factor family are chronically phosphorylated in the failing heart as a result of IHD (STAT1 and 5) or DCM (STAT1, 3, 5 and 6). In contrast, IHD but not DCM showed significant p38 MAPK phosphorylation. Whilst the differences noted between IHD and DCM may reflect different initiating events, the common activation of STATs I and 5 suggests that these transcription factors may play a common role regulating the progression of heart failure. (C) 2003 European Society of Cardiology. Published by Elsevier Science B.V. All rights reserved.
U2 - 10.1016/S0008-6363(02)00664-8
DO - 10.1016/S0008-6363(02)00664-8
M3 - Article
VL - 57
SP - 333
EP - 346
JO - Cardiovascular Research
JF - Cardiovascular Research
SN - 0008-6363
ER -